Who Pays for Stem Cell Research? A Beginner's Guide to How Trials and Therapies Get Funded

When people hear "stem cell breakthrough," they rarely ask who paid for it — but the answer matters enormously for anyone trying to tell real medical progress from a marketing pitch. Stem cell research moves through a fairly predictable funding relay: government agencies and nonprofits typically fund the earliest, riskiest science; universities host it; and only once an idea shows real promise does private industry — venture capital and biotech companies — step in to fund the expensive clinical trials needed for FDA approval. Understanding this pipeline is one of the most practical tools a patient can have, because it explains a rule that trips up a lot of people: legitimate research is subsidized by grants and investors, not by the patients who enroll in it, which is exactly why a clinic asking you to personally pay thousands of dollars for an "investigational" stem cell product is a major red flag.

How Government Money Starts the Process

Almost every stem cell therapy in existence traces its origins back to publicly funded basic research. In the United States, the largest funder of biomedical science is the National Institutes of Health (NIH), which operated on a total budget of roughly $47 billion in fiscal year 2025. NIH funds stem cell research specifically through grants tracked in its Research, Condition, and Disease Categorization system, which has historically shown non-embryonic and induced pluripotent stem cell (iPSC) research receiving considerably more funding than human embryonic stem cell research — for example, compiled NIH data show non-embryonic stem cell funding of roughly $861 million versus about $213 million for embryonic research in 2017, the most recent year with a detailed public breakdown of that kind. These grants typically go to university and academic medical center labs, not to companies, and they fund the "discovery" phase: identifying which cells do what, how they might be coaxed into becoming a therapy, and whether an idea is safe enough to test further.

State governments can also become major funders in their own right. The most prominent example is California's stem cell agency, the California Institute for Regenerative Medicine (CIRM), created when voters passed Proposition 71 in 2004 and authorized it $3 billion in bond funding. When that money neared exhaustion, voters approved Proposition 14 in 2020, adding another $5.5 billion — bringing CIRM's total voter-authorized funding to roughly $8.5 billion, one of the largest state-level commitments to a single area of medical research anywhere in the world. CIRM funds everything from basic lab discovery grants to clinical trials and has supported a network of "Alpha Stem Cell Clinics" designed to run trials to a consistent standard. A handful of other states, including Maryland through its Stem Cell Research Fund, run smaller versions of the same model.

From University Lab to Company: The Translation Gap

Public grants are generally not designed to carry a discovery all the way to a marketed product — that final stretch, called "translation," is enormously expensive, and it's where private industry usually takes over. A well-documented example is CAR-T cell therapy, a form of engineered immune-cell treatment for cancer. Foundational work happened in academic labs, including Carl June's laboratory at the University of Pennsylvania. In 2012, Penn entered into a research and licensing collaboration with the pharmaceutical company Novartis, which funded the manufacturing scale-up and the large, expensive clinical trials required for approval. That partnership led to the 2017 FDA approval of Kymriah (tisagenlecleucel), the first CAR-T therapy ever approved — illustrating the typical handoff: academic and public funding proves a concept works in principle, then a company licenses the technology, invests heavily, and runs it through the regulatory gauntlet.

This university-to-industry handoff usually happens through a formal technology transfer office, which patents the discovery on the university's behalf and licenses it to a company in exchange for licensing fees, milestone payments, and often a share of future royalties — money that, in many cases, flows back into funding more university research.

Venture Capital and Biotech Industry Investment

Once a discovery looks commercially promising, venture capital becomes a central funding source. Cell and gene therapy investment has been volatile: it peaked around $8.2 billion across roughly 121 deals in 2021 during a broader biotech boom, fell substantially as investor enthusiasm cooled — to about $3.5 billion across 65 deals in 2023 — and has continued fluctuating since. This volatility matters for patients to understand: a company's ability to keep a promising therapy moving through trials can depend heavily on the state of the investment market, not just on the science. Clinical trials are enormously costly — commonly estimated to run from tens of millions to well over a billion dollars per approved drug when failures are factored in — which is why so few academic discoveries ever reach a company able to fund the multi-year trial process, and why even fewer of those trials end in FDA approval.

The Role of Nonprofits and Disease Foundations

Disease-specific nonprofits are a quieter but important piece of the funding picture, often filling gaps between government grants and venture capital. The Michael J. Fox Foundation for Parkinson's Research, for instance, announced more than $309 million in research grants in 2024 alone, including funding for stem cell projects such as generating new induced pluripotent stem cell lines for the broader research community to study Parkinson's disease. Many disease foundations now practice "venture philanthropy," in which they fund early-stage academic or biotech research in exchange for a stake in future returns if a therapy succeeds — money that, like state and federal grants, is intended to de-risk the earliest, most uncertain stage of research so that private investors are more willing to fund the expensive trials that follow.

Why Legitimate Trials Don't Charge Patients — and Why That Matters

This funding chain explains one of the most important things a beginner can learn about stem cell medicine: in a legitimate clinical trial, the investigational product itself is not something you pay for. Trial sponsors — companies, universities, or government agencies — cover the cost of the treatment because they are the ones trying to gather data to prove it works; charging participants would undermine the scientific and ethical basis of the trial. The FDA has stated this directly in consumer guidance, warning that "if you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally." Patients may still have costs — travel, routine standard-of-care visits not covered by insurance, sometimes lodging — but being asked to pay a large sum specifically for the stem cell product itself, especially at a clinic advertising outside of a registered, monitored trial, is a signal that something is off.

How to Tell Real Research Funding from Marketing

Because legitimate stem cell research funding leaves a paper trail — NIH grant numbers, CIRM award listings, SEC filings for public biotech companies, or named foundation grants — patients and caregivers can do some of their own due diligence. A treatment backed by real research funding will typically be registered on ClinicalTrials.gov, will be able to point to a specific sponsor (a university, a company, a foundation, or a federal agency), and will not ask patients to fund the experimental product out of pocket. A clinic that instead emphasizes patient testimonials, requires large upfront payments, and can't point to a registered trial or public funding source is operating outside the system this article describes — and that gap is often the clearest sign that a therapy hasn't actually been proven safe or effective.

Bottom Line

Stem cell therapies don't appear out of nowhere — they move through a long, expensive relay of funders, starting with taxpayer-funded NIH and state grants (like California's roughly $8.5 billion CIRM program), continuing through university labs and nonprofit foundations, and finally reaching biotech companies and venture capital investors willing to fund the costly clinical trials FDA approval requires. That structure exists because proving a therapy is safe and effective is expensive and uncertain, and spreading that cost across public, philanthropic, and private funders — rather than billing patients directly for an unproven product — is what keeps the incentives aligned toward real evidence. For patients, understanding this pipeline is a practical tool: a treatment with a traceable funding history and a registered trial is playing by very different rules than a clinic asking you to pay cash for a product it calls "investigational."